Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC ...Middle East

SEONGNAM, South Korea and NEWTON, Mass., Oct. 30, 2023 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced that the company has initiated the Phase 1/2 clinical trial...

Read More Details
Finally We wish PressBee provided you with enough information of ( Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-207 in EGFR-Mutant NSCLC )

Also on site :

• Golf: JJ Spaun wins rainy US Open for first major title
• Israeli rescuers say latest Iran strikes kill five, wound 92
• Nitish Rana and wife Saachi Marwah blessed with twins, share adorable post